The DNA damage response (DDR) network is exploited by cancer cells to withstand chemotherapy. Gastric cancer (GC) carries deregulation of the DDR and harbors genetic defects that fuel its activation. The ATM-Chk2 and ATR-Chk1-Wee1 axes are deputed to initiate DNA repair. Overactivation of these pathways in cancer cells may represent an adaptive response for compensating genetic defects deregulating G 1 -S transition (e.g., TP53) and ATM/ATR-initiated DNA repair (e.g., ARID1A). We hypothesized that DDR-linked biomarkers may predict clinical outcomes in GC patients treated with chemotherapy. Immunohistochemical assessment of DDR kinases (pATM, pChk2, pChk1 and pWee1) and DNA damage markers (c-H2AX and pRPA32) was performed in biological samples from 110 advanced GC patients treated with first-line chemotherapy, either in phase II trials or in routine clinical practice. In 90 patients, this characterization was integrated with targeted ultra-deep sequencing for evaluating the mutational status of TP53 and ARID1A. We recorded a positive association between the investigated biomarkers. The combination of two biomarkers (c-H2AX high /pATM high ) was an adverse factor for both progression-free survival (multivariate Cox: HR 2.23, 95%CI: 1.47-3.40) and overall survival (multivariate Cox: HR: 2.07, 95%CI: 1.20-3.58). The relationship between the c-H2AX high /pATM high model and progression-free survival was consistent across the different TP53 backgrounds and was maintained in the ARID1A wild-type setting. Conversely, this association was no longer observed in an ARID1A-mutated subgroup. The c-H2AX high /pATM high model negatively impacted survival outcomes in GC patients treated with chemotherapy. The mutational status of ARID1A, but apparently not TP53 mutations, affects its predictive significance.
DNA damage and repair (DDR) pathways protect eukaryotic cells from genotoxic injuries ensuring the transmission of an unaltered genetic code to the progeny. 1 This complex genome-protecting network is aberrantly exploited by cancer cells to tolerate the high levels of DNA damage they accumulate. Indeed, the genome of cancer cells is threatened by a variety of endogenous substances and deregulated processes, including: i) the elevated production of reactive oxygen species related to the increased metabolic demands (oxidative DNA damage), 2 ii) the replicative stress imposed by activating mutations in oncogenes that control cell proliferation 3 and iii) the defective nature of the G 1 /S checkpoint (e.g., TP53 mutations) that renders cancer cells "addicted" to intact cell cycle control systems for determining cell fate upon DNA damage. 4 The crosstalking ataxia-telangiectasia mutated (ATM)-checkpoint kinase 2 (Chk2) and ataxia telangiectasia and Rad3-related protein (ATR)-checkpoint kinase 1 (Chk1)-Wee1-like protein kinase (Wee1) axes operate in the intra-S and G 2 /M checkpoints. 5, 6 When DNA single-and double-strand breaks (SSBs and DSBs) occur, ATR-Chk1-Wee1 and ATM-Chk2 pathways halt the cell cycle and coordinate DNA repair or selfelimination of irreversibly damaged cells, depending upon the entity of the damage and repair capabilities. 5 In cancer cells, DNA damage often arises in a background of defective G 1 /S transition; within this molecular frame activation of ATMChk2 and ATR-Chk1-Wee1 pathways becomes crucial to avoid entry into a defective and lethal mitosis. We hypothesized that this adaptive response may represent a sort of "molecular side effect" through which cancer cells are predisposed to efficiently handle exogenous (therapeutic) sources of DNA damage, such as chemotherapy. 7, 8 Molecular characterization of gastric cancer (GC) revealed ATM/ATR activation across all the molecular subtypes. 9 Moreover, a number of genes associated with their signaling are recurrently altered in GC, including genes linked to defective cell cycle control (e.g., TP53) and altered initiation of the DDR cascade (e.g., ARID1A). 9 We reasoned that aberrant activation of the DDR in GC, supposedly driven or enforced by the underlying genetic portrait of the disease, may be exploited in the search for biomarkers predicting chemotherapy sensitivity/resistance. To test this hypothesis, biological samples from 110 GC patients treated with first-line chemotherapy in prospective phase II trials or in routine clinical practice, [10] [11] [12] [13] were retrospectively evaluated by immunohistochemistry (IHC) for assessing the expression of DDR kinases (pATM, pChk2, pChk1 and pWee1) and DNA damage markers, namely the DNA DSB marker phosphorylated H2A histone family member X (g-H2AX) and the single-stranded DNA/SSB marker phosphorylated replication protein A2 (pRPA2, best known as pRPA32). Mutation analysis of TP53 and ARID1A was conducted in 90 patients to investigate whether specific genetic events with elevated mutational rates impacted the predictive significance of most promising markers.
Patients and Methods

Patients
Written informed consents were obtained by all the participants. The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the "Regina Elena" National Cancer Institute of Rome. This study adheres to the REMARK guidelines. 14 To define positive and negative cases, a classification comparable to that of our previous studies was used. 7, 8 DNA damage markers (g-H2AX and pRPA32) were classified as high and low/negative using the median score of all tumors as the cut-off points. Median percentages of nuclearexpressing cells for g-H2AX and pRPA32 were 30% and 40%, respectively. For DDR kinases, samples were considered positive when 20% of the neoplastic cells showed a distinct nuclear immunoreactivity of any intensity. Immunoreactivity was evaluated by two investigators blinded to treatment outcomes (LR and EM) and discordant cases were reviewed by a third observer (MM and SB). Immunohistochemical staining of two representative cases is presented in Supporting Information Figure 1 .
Targeted DNA deep sequencing
Genomic DNA was extracted from 5 mm FFPE tissue sections using the AllPrep DNA/RNA FFPE kit (Qiagen, Valencia, CA). To perform the targeted DNA resequencing of ARID1A and TP53, a custom panel employing DesignStudio from Illumina was designed. The library was prepared using the TruSeq Custom Amplicon Low Input Kit following the manufacturer's instructions. Sequencing was carried out on a NextSeq 500 (Illumina, San Diego, CA) in paired-end mode, sequencing from each side 150 bp. Primary analysis encompassing FASTQ file generation, alignment and variant calling was performed on the Illumina BaseSpace Cloud environment, using the Truseq Amplicon analysis pipeline version 2.0. TSV files were generated from VCFs with the Illumina Variant Studio software. From TSV files, we filtered out lowcoverage (<2003), dbSNP annotated variants (MAF >5%) and mutations that did not lead to an amino acid change in the protein. Afterwards, TP53 and ARID1A mutations were further filtered on the basis of the following criteria: i) allele frequencies 10%, ii) having a COSMIC ID and iii) annotated as oncogenic in cBioPortal Version 1.2.5, last accessed on September 21. The experimental workflow is summarized in Supporting Information Figure 2 .
Statistical analyses
The Pearson's Chi-squared test of independence (two tailed) or the Fisher exact test, depending upon the size of the groups compared, were employed for investigating the relationship between categorical variable. The correlation between DDR biomarkers, when analyzed as continuous variables (percentage of nuclear-expressing cancer cells), was assessed with the Pearson's correlation coefficient. Survival curves were estimated with the Kaplan-Meier product-limit method and compared by log-rank test. Variables potentially affecting PFS and OS were tested in univariate Cox 
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proportional hazard models. Multivariate Cox models were built with variables testing significant at the univariate analysis and by stepwise regression through backward elimination. The related estimates were reported as hazard ratio (HR) and 95% confident interval (CI). Cross-validation was used for assessing the robustness of the molecular background of interest (H2AX high /pATM high ); univariate Cox analysis was carried out on the group of patients treated in phase II trials (training set) and then on the group of patients treated in routine clinical practice (validation set). Level of significance was defined as p < 0.05. Statistical analyses were carried out using SPSS version 21.0 (SPSS, Chicago, IL).
Results
Baseline characteristics of the patients and expression pattern of DDR biomarkers
Baseline characteristics of the 110 patients included in the present analysis are summarized in Table 1 . Median age at diagnosis was 60.8 years. Seventy-two (65.5%) patients had metastatic disease, whereas 38 (34.5%) patients received chemotherapy for inoperable locally advanced disease. Regarding chemotherapy regimens, 68 (61.8%) patients received threedrug regimens, and taxane-containing chemotherapy was administered to 61 (55.5%) patients. Fifty-six patients were treated in prospective phase II trials. Distributions of DDR biomarkers did not significantly differ by treatment received in the first-line setting, i.e., number of therapeutic agents and taxane administration (data available upon request). We recorded a significant positive association between DDR biomarkers (Fig. 1, panel a) ; a significant correlation between the various markers was also observed when they were analyzed as continuous variables considering the percentage of nuclear-expressing tumor cells (Fig. 1, panel b) .
DDR biomarkers and PFS, sensitivity analysis and outliers analysis
Patients whose tumors had elevated expression levels of g-H2AX experienced significant shorter PFS compared with their negative counterparts (log rank p 5 0.001) (Fig. 2, panel  a) , and a non significant association was observed for pATM (log rank p 5 0.081) (Fig. 2, panel b) . A model of double positivity (g-H2AX high /pATM high ) was also significantly associated with shorter PFS (log rank p < 0.001) (Fig. 2, panel c) . Similar results emerged from a sensitivity analysis carried out on patients with metastatic disease, thus excluding patients with locally advanced tumors (Supporting Information Fig.  3 ). In the entire cohort, we did not appreciate any association between pChk1, pWee1, pRPA32 and pChk2 and PFS (data available upon request). Nevertheless, a significant association was observed between g-H2AX, pATM and pChk1 expression and negative and positive outliers, namely patients in the lowest (PFS < 3 months) and highest (PFS > 10 months) quartile (N 5 54), with a trend toward statistical significance for pRPA32 (p 5 0.057, Supporting Information Table 2 ). 
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Thus, an extensive activation of upstream branches of the DDR machinery may delineate a fraction of patients with intrinsically chemoresistant GC.
Uni-and multivariate cox regression models for PFS and OS, cross-validation
As our results suggested a prominent role of DSB repair avenues in feeding chemoresistance, the g-H2AX high /pATM high phenotype was verified in uni-and multivariate Cox models for PFS and OS. Uni-and multivariate Cox regression analyses revealed that patients with double-positive tumors were at increased risk of progression (multivariate Cox: HR 2.23, 95%CI: 1.47-3.40, p < 0.001) ( Table 2 ). The consistency of the H2AX high /pATM high model was further confirmed upon cross-validation (Supporting Information Fig. 4) . Uni-and multivariate Cox models for OS (Table 3) 
Predictive significance of DDR biomarkers according to TP53 and ARID1A mutations
Basal DDR activation may stem from the underlying genetic portrait of the disease, as a number of frequently mutated genes in GC were preclinically tied to the activation of the intra-S and G 2 /M checkpoints. To address this issue, targeted deep resequencing was conducted to evaluate TP53 and ARID1A mutational status in 90 patients with sufficient biological materials. As shown in Figure 3 (panel a), 53% and 47% of the samples harbored TP53 and ARID1A mutations, respectively (detailed information in Supporting Information Table 3 ). To investigate whether the genetic status of TP53 and/or ARID1A impacted the predictive ability of the g-H2AX high /pATM high model, univariate Cox analyses were carried out in the different genetic contexts. The relationship between the g-H2AX high /pATM high model and PFS was independent on TP53, albeit to a borderline significant extent in the TP53-mutated setting (p 5 0.052) (Fig. 3, panel b) . Likewise, the H2AX high /pATM high model continued to be associated with an increased risk of disease progression in the ARID1A wild-type background. Conversely, this relationship was lost in the ARID1A-mutated setting (Fig. 3, panel b) . 
Discussion
We herein examined the expression pattern of central orchestrators of the DDR response in a relatively large series of advanced GC patients treated with first-line therapy. Approximately half of these patients received chemotherapy in prospective phase II trials. [10] [11] [12] [13] As activation of the ATM-Chk2/ ATR-Chk1-Wee1 cascade may be related to, or enforced by, genetic events altering cell cycle progression and DNA repair efficiency, the mutational status of top-ranking mutated genes in GC (TP53 and ARID1A) was assessed. Our results suggest that i) a subset of GC is characterized by a robust DDR activation, ii) activation of the system that signals the presence of DSBs may be detrimental for these patients conferring chemoresistant features, as denoted by uni-and multivariate Cox models for PFS and OS and iii) the clinical relevance of this process may be independent on TP53 status, whereas it seemed affected by protein-damaging ARID1A mutations.
Our study, which is hypothesis-generating in nature, raised a number of points that may streamline the identification of efficient DDR-related predictive factors. In the search for molecular determinants, anticipating the benefits patients receive from chemotherapy, the focus was mostly placed on single effectors acting within a specific repair avenue deputed to correct a given type of genetic lesion. 16, 17 Our results suggest that molecular mechanisms through which cancer cells sense DNA damage and the way this information is transmitted/amplified should not be underestimated in future investigations.
The lesson learned from preclinical investigations striving to elucidate how cancer cells exploit the DDR to survive chemotherapy is that protein-protein interactions should be viewed in light of genetic contexts that, at the level of protein function, intersect these communications. 18, 19 For instance, pharmacological inhibitors of upstream DDR kinases were originally advocated as synthetically lethal therapeutics for targeting p53-defective tumors. 18, 19 We neither observed an impact of TP53 mutations on the predictive ability of DDR markers, nor any association between TP53 status and the investigated molecular endpoints was found (data available upon request). Albeit these data may question the idea of an intra-S/G 2 -M checkpoint dependency of p53-defective tumors, two not mutually exclusive molecular mechanisms deserve mention. First, TP53 mutations not invariably result in a defective protein, but rather some missense mutations (overall accounting for 75% of all TP53 mutations) encode for a protein with oncogenic potential (gain-offunction mutations). 20 Even though these mutated p53 forms exert a dominant-negative effect on wild-type p53, they also endow the new protein with tumor-promoting abilities. 20 Second, GC harbors amplification of cyclins (e.g., CCNE1 and CCND1) and cyclin-dependent kinases (e.g., CDK6) that drive cells from G 1 into S phase, suggesting the existence of another level of deregulation at the G 1 -S transition beyond loss of p53 function. 9 Tailored preclinical investigations are warranted for the correct interpretation of how the different spectrum of TP53 lesions, together with other defects in the G 1 -S transition machinery, lead to intra-S and G 2 /M checkpoint dependency and fuel chemoresistance.
Next, the tumor suppressor ARID1A, a subunit of the SWI/ SNF chromatin remodeling complex, was identified as frequently mutated in a broad spectrum of tumors. 21 It was recently demonstrated that ARID1A is recruited to DNA DSBs via 
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ATM/ATR signaling where it facilitates the processing of DNA lesions.
22 ARID1A-deficient cells displayed impaired initiation and maintenance of the G 2 -M checkpoint and overall a suboptimal response to DSBs. Moreover, ARID1A suppression resulted in reduced non-homologous end joining activity and sensitized cell lines to cytotoxic agents. 23 As we did not observe any association between DDR markers and an increased risk of disease progression in the ARID1A-mutated setting, we speculate that defective ARID1A function may interfere with molecular mechanisms conferring chemoresistant traits. To provide further ground to this observation, we strive to establish a collection of patient-derived cancer (stem) cell lines and xenografts. There are several reasons behind this choice: i) even though our data suggest a connection between ARID1A status, the DDR and sensitivity/resistance to chemotherapy, we were unable to conduct mechanistic in vitro studies given the limited availability of commercially available (e.g., ATCC) GC cell lines carrying ARID1A mutations, ii) prospectively isolated patient-derived GC cells and xenografts are expected to better recapitulate the molecular portrait of the parental tumors compared with commercial cell lines, 24 which expose investigators to a number of potential biases (e.g., cross-contamination, molecular artifacts stemming from multiple passages in culture) and whose clinical usefulness is the focus of intense debate in the scientific community. 25 Moreover, prospective isolation and characterization of patient-derived GC cells will enable us to combine mechanistic and correlative studies, iii) the majority of commercially available GC cell lines were obtained from patients of Asian ethnicity, and it is known that non-negligible differences exist between GC arising in Asians and Caucasians, both at the molecular and clinical level. [26] [27] [28] A third level of genetic characterization that should be pursued refers to oncogene-induced replication stress. This condition is characterized by increased numbers of stalled or collapsed replication forks that elicits an ATM-ATRdependent response.
3 MYC overexpression/amplification is among the best characterized condition underlying oncogeneinduced replication stress, and inhibition of DDR kinases was proposed as a synthetic lethality-based approach for targeting MYC-driven tumors. 29, 30 Approximately 15% of GCs carry MYC amplification/mutation and a "target of MYC activation" signature was found to be active in all the four GC subtypes. 9 A mention deserves the positive association in the expression of the investigated markers (Fig. 1) , which suggests a robust activation of the DDR response in a subset of GC patients. This finding potentially holds therapeutic perspective in light of the number of cell cycle checkpoint inhibitors that have entered clinical development over the past years. 18 Even though results from pioneering clinical trials dampened the expectations around these compounds, 18 these studies were weakened by lack of biomarker analysis. Our study may represent a first step toward delineating the target population for clinical trials with cell cycle checkpoint inhibitors, enforcing the concept that extensive DDR pathway analysis should be carried out both at the protein and genetic levels to streamline the development of these compounds. Finally, our interest toward the identification of DDRlinked predictive biomarkers prompted us to initiate a further level of molecular characterization, with special emphasis being placed on the Fanconi Anemia (FA) pathway. The FA pathway is involved in DNA interstrand crosslink (ICL) repair, 31 and its overactivation was found to be a shared trait across the four molecular subtypes identified by the TCGA. 9 To this end, we activated a multicenter, retrospective study in an expanded case series with the aim of investigating the predictive significance of various FA pathway markers. More specifically, we planned the study of FA pathway components involved in lesion recognition (e.g., FANCM), components of the FA core complex (e.g., FANCA to FANCT) and the ERCC4-ERCC1 complex, which is central in unhooking ICL lesions.
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Conclusion
Our data pointed to the activation of upstream regulators of the DDR machinery as potential biomarkers for predicting the efficacy of chemotherapy in GC patients. Prospective validation of these encouraging findings, together with a deeper characterization of genetic events tied to the processing of DNA lesions, is advised to gain a better understanding on how this information can be transferred into the clinical setting.
